Compare SFST & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SFST | ENTA |
|---|---|---|
| Founded | 1999 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 421.9M | 486.3M |
| IPO Year | 1999 | 2013 |
| Metric | SFST | ENTA |
|---|---|---|
| Price | $56.52 | $13.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $51.00 | $20.40 |
| AVG Volume (30 Days) | 51.4K | ★ 244.7K |
| Earning Date | 01-22-2026 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 96.33 | N/A |
| EPS | ★ 3.75 | N/A |
| Revenue | ★ $115,139,000.00 | $65,324,000.00 |
| Revenue This Year | $11.98 | $0.99 |
| Revenue Next Year | $13.21 | $0.19 |
| P/E Ratio | $14.67 | ★ N/A |
| Revenue Growth | ★ 23.49 | N/A |
| 52 Week Low | $29.14 | $4.09 |
| 52 Week High | $58.77 | $17.15 |
| Indicator | SFST | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 59.38 | 48.17 |
| Support Level | $53.18 | $12.45 |
| Resistance Level | $58.77 | $13.03 |
| Average True Range (ATR) | 2.25 | 0.63 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 76.04 | 61.11 |
Southern First Bancshares Inc is a bank holding company. The company engaged in the business of accepting demand deposits and savings deposits insured by the Federal Deposit Insurance Corporation (the FDIC), and providing commercial, consumer and mortgage loans to the general public of which a majority of the revenue is derived from the Commercial and Retail Banking segment which includes the provision of traditional deposit and lending products and services to its commercial and retail banking clients.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.